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Abstract
Background: In Wilson disease, copper is not sufficiently excreted into bile due to the absence
or malfunction of the Wilson protein copper ATPase in the excretory pathway of hepatocytes.
Copper is found in sweat. It is unknown if the Wilson protein plays a role in copper excretion into
sweat. It is the aim of this study to investigate Wilson protein expression in sweat glands and
analysing its effects on copper excretion into sweat in controls and patients with Wilson disease.
Methods: Immunofluorescent analysis of the Wilson protein in skin samples from normal rat, LEC
rat and human skin biopsies were performed. Pilocarpin-induced sweat gland stimulation by
iontophoretic transfer adapted from the methods used for cystic fibrosis sweat test was used for
sweat induction. Sweat volume, sweat copper concentration, serum ceruloplasmin and serum
copper were analysed in 28 Wilson patients and 21 controls.
Results:  The Wilson protein is expressed in human and rat sweat gland epithelia. Copper
concentration in sweat is not significantly different between controls and Wilson patients. Wilson
patients produce significantly smaller volumes of sweat compared to controls. Sweat production is
partially reversible in Wilson patients under medical treatment for Wilson disease or after liver
transplantation
Conclusion: Wilson patients show a reduced sweat production with unaltered sweat copper
concentration. The Wilson protein might play an important role in physiological sweat production.
Background
Wilson disease is an autosomal recessive disease of copper
metabolism [1-3]. Mutations in the Wilson gene Atp7b
result in an absence or malfunction of the Wilson protein
[4]. The Wilson protein is a transmembranous copper
ATPase located in the trans-Golgi-network of human cells
providing copper to cuproenzyms such as ceruloplasmin.
The Wilson protein can move within the cell from the
trans-Golgi-network to a late endosomal compartment
when intracellular copper concentrations are elevated. In
this cellular localization it has an important function in
copper excretion out of the cell as copper is excreted via
this late endosomal compartment out of the cell. The Wil-
son protein is mainly expressed in hepatocytes. Biliary
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excretion of excessive copper is one of the central func-
tions of the Wilson protein [5]. However, Wilson protein
is also expressed in other tissues such as kidney, brain,
intestine and heart [6]. Patients with Wilson disease usu-
ally develop symptoms between the age of 5–70 years.
Patients often have hepatic changes due to the copper
accumulation in the liver, e.g. liver cirrhosis, fatty liver dis-
ease, elevated liver enzymes, acute liver failure. Neurolog-
ical or psychiatric symptoms can also be seen in Wilson
patients (e.g. tremor, gait disturbance, blurred speech,
increased mucle tone, depression) [7]. Hyperpigmenta-
tions at the lowers legs have been associated as rare der-
matological manifestation of Wilson disease [8].
Treatment of Wilson disease with the copper chelating
agent D-penicillamine can result in therapy induced
changes like loss of elastic fibres, pseudoxanthoma elasti-
cum with elastosis perforans serpiginosa [9], cutis laxa
[10] and others summarized as the D-penicillamin-
induced degenerative dermatosis [11]. The alternative
copper chelator trientine results in a smaller number of
skin changes. Copper can be detected in human sweat
[12-16]. Copper concentrations in sweat show interindi-
vidual variations and to a lesser degree intraindividual
variations. Copper concentrations vary depending on the
collection area [13]. During exercise, copper sweat excre-
tion is stable [14]. Females show slightly lower copper
concentration in sweat than men. However, in situations
resulting in higher serum levels of the cuproenzyme ceru-
loplasmin such as pregnancy or under medication result-
ing in anovulation for anticonception purposes, women
have higher sweat copper levels [15]. In the past, sweat has
been collected by applying platic bags or filter papers to
certain skin areas and exposing test persons to exercise or
humidity and heat (sauna) or by pilocarpin induced
ionotopheresis followed by sweat collection with filter
papers [16]. The mechanisms of copper excretion into
sweat are not characterized so far. Diffusion, passive trans-
port or paracellular transport from surrounding tissues or
serum molecules into the sweat, as described previous for
other compounds such as ethanol [17] or lactate [18],
could be potential mechanisms for copper excretion into
sweat. As copper is a highly reactive reagent due to its
potential to oxidize or reduce reaction partners, nature
has evolved with a number of copper-binding und cop-
per-handling proteins such as Atox1, COMMD1, COX 17,
CCS resulting in a directed and safe handling of copper
within the cell and the body [6]. Sunderman et al.
reported of 2 Wilson patients with reduced sweating dur-
ing sauna bathing [19]. Therefore this study was aimed to
investigate Wilson protein expression in sweat glands and
analysing its effects on copper excretion into sweat in con-
trols and patients with Wilson disease. The goals of this
study were investigating Wilson protein in sweat glands,
developing a scientific method of sweat collection and
copper determination in Wilson patients and analysing
sweat volumes and copper excretion in Wilson patients
and controls as a potential diagnostic tool for Wilson dis-
ease.
Methods
Patients and controls
The procedures performed within this study both in
humans and animals have been approved by the local
ethic committees (No. 346/2005) and are in compliance
with the Helsinki Declaration. Informed consent was
obtained from each patient prior to sweat tests and
obtaining blood. As shown in Table 1, the sex distribution
and average age of the Wilson patients and controls
reflected the age group treated in the institution [7]. In 4
untreated Wilson patients, sweat volume was to low to
measure copper concentrations. These patients were not
included in the statistical analysis of the sweat copper con-
centrations. Of the 23 patients under treatment, 15 were
treated with D-penicillamin therapy, 4 with trientine, 3
patients with zinc and 1 patient was on a combination
therapy of zinc and trientine at the time of the sweat test.
Table 2 outlines the detailed data of each patient. Patients
37 and 49 have been measured at 2 time points.
Sweat test
A standardized method was developed for studying cop-
per excretion in sweat stimulated by pilocarpin-ionto-
phoreses: Sweat samples were obtained by a standardized
protocol at the forearms of patients and controls: The skin
was cleaned thoroughly with disinfection solution (iso-
propanol) and distilled water, respectively. Sweat produc-
tion was stimulated by a 5 minute iontophoretic transfer
(1.5 mA, max.35 V) of 0.5% pilocarpin solution into the
skin at an area of about 4 cm2 using a standardized ionto-
phoretic unit used for cystic fibrosis sweat test (Wescor
company). After cleaning the test area with destilled
water, a modified sweat collector system with an collec-
tion area of 3.6 cm2 (Macroduct, Wescor) was applied for
30 minutes. Due to the clinical setting, sweat tests were
not standardized for the time of the day when sweat col-
lections were done, the humidity or temperature of the
room, the diet of the test persons, even though some of
these factors may influence the sweat production. Poten-
tial effect on non-pilocarpin-dependent sweat production
might also influence our results and were not analysed
separately. Multiple sources of copper contamination had
to be removed from the material commercially available
for cystic fibrosis sweat tests including the standard pilo-
Table 1: Patients and controls included in study
Number Male/Female Age ± SD
Wilson patients 28 8/20 32 ± 10
Controls 21 11/10 32 ± 2BMC Gastroenterology 2008, 8:29 http://www.biomedcentral.com/1471-230X/8/29
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Table 2: Detailed data of all patients included into the study
No Group Age [years] Sex
M = male
F = female
Sweat copper 
concentration [μmol/l]
Sweat volume [μl] Remarks
1 Control 25 F 2.98 80.0
2 Control 32 F 1.85 69.0
3 Control 25 F 2.89 33.0
4 Control 28 M 1.66 37.4
5 Control 31 F 2.89 40.0
6 Control 23 F 2.59 44.0
7 Control 37 F 1.18 76.0
8 Control 29 M 2.00 122.0
9 Control 30 M 5.06 74.0
10 Control 25 M 1.27 82.0
11 Control 49 M 1.43 92.0
12 Control 31 F 2.58 38.0
13 Control 25 M 2.54 47.0
14 Control 30 M 1.34 34.0
15 Control 49 F 5.66 15.0
16 Control 52 F 2.68 57.0
17 Control 30 M 2.59 62.0
18 Control 24 M 1.29 29.0
19 Control 30 F 1.77 94.0
20 Control 25 M 1.30 116.0
21 Control 33 F 2.23 95.0
22 Wilson patient on medication 54 M 2.03 36.0 D-penicillamin
23 Wilson patient on medication 25 F 1.99 30.9 trientine/zinc
24 Wilson patient on medication 34 F 9.94 25.0 D-penicillamin
25 Wilson patient on medication 19 F 4.93 26.0 D-penicillamin
26 Wilson patient on medication 19 F 2.84 37.0 D-penicillamin
27 Wilson patient on medication 21 M 2.54 41.5 D-penicillamin
28 Wilson patient on medication 25 F 3.97 38.0 D-penicillamin
29 Wilson patient on medication 41 F 0.34 42.2 zinc
30 Wilson patient on medication 36 M 3.02 58.0 D-penicillamin
31 Wilson patient on medication 43 F 0.82 40.2 D-penicillamin
32 Wilson patient on medication 25 M n.d. 1.0 D-penicillamin
33 Wilson patient on medication 53 F 0.40 70.0 zinc
34 Wilson patient on medication 32 F 1.94 31.0 trientine
35 Wilson patient on medication 38 F n.d. 1.4 D-penicillamin
36 Wilson patient on medication 24 F 2.75 27.0 D-penicillamin
37 Wilson patient on medication 37 M 2.62 31.6 trientine
38 Wilson patient on medication 31 F 6.74 32.2 trientine
39 Wilson patient on medication 43 F 3.78 53.0 D-penicillamin
40 Wilson patient on medication 46 F 3.18 35.0 D-penicillamin
41 Wilson patient on medication 23 M 1.41 81.0 D-penicillamin
42 Wilson patient on medication 18 F 3.02 38.0 D-penicillamin
44 Wilson patient on medication 24 M 1.49 86.0 trientene
45 Wilson patient on medication 42 M 3.11 36.0 zinc
46 Wilson patient without therapy 33 F 3.00 23.0 no therapy
47 Wilson patient without therapy 18 F n.d. 6.0 Acute liver failure before 
liver transplantation
37 Wilson patient without therapy 37 M n.d. 0.0 initial diagnosis, before 
therapy
48 Wilson patient without therapy 18 F n.d. 0.0 Acute liver failure before 
liver transplantation
49 Wilson patient without therapy 56 F n.d. 0.3 No therapy, compliance 
problem
50 Wilson patient without therapy 23 F n.d. 12.0 Initial diagnosis, before 
therapy
49 Wilson patient after liver 
transplantation
20 F n.d. 46.0 6 months after liver 
transplantationBMC Gastroenterology 2008, 8:29 http://www.biomedcentral.com/1471-230X/8/29
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carpin containing agarose-gel discs and the dye making it
easier to detect sweat in the collection tube. Every step of
the procedure was investigated separatly in order to abol-
ish any kind of contamination during the whole process
of sweat simulation, sweat collection and sweat handling/
storage. The validity of the results obtained becomes obvi-
ous when comparing previous result obtained in studies
analysing copper excretion in sweat, either during exer-
cise, during sauna bathing or stimulated by pilocarpin.
The copper concentrations obtained in this study are well
in the range of the reported data [12-16,19]. The volume
of the sweat samples was determined. The copper concen-
tration was measured by atomic absorption. Total copper
excretion was calculated (volume × copper concentra-
tion).
Out of blood samples obtained during sweat collection,
serum copper and ceruloplasmin concentrations were
determined by standard laboratory methods.
Immunofluorescence
For immunofluorescence studies, a polyclonal antibody
directed against the copper binding sites 4–6 of the Wil-
son protein was utilized in frozen sections of rat paws and
an human autopsy skin sample embedded in a standard
embedding solution (Tissue Tec) as outlined before [5].
Counterstainings were perfomed with Haematoxylin-
Eosin and a blue fluorescent DNA-binding dye
(Hoechst®).
Statistical analysis
Statistical analyses were performed with SPSS for Win-
dows, release 10.05 (SPSS, Chicago, IL). Comparisons of
quantitative variables were performed by the unpaired
Mann-Whitney-Test test. Data are means ± SD. A P value
< 0.05 was considered as statistically significant.
Results
Wilson protein in sweat glands
Immunofluorescent studies in frozen sections of human
and rat skin utilizing a Wilson protein antibody demon-
strated abundant expression of the Wilson protein in the
secretory and ductular epithelial cells of the sweat glands
both in human and rat (Figure 1). There was no signal
obtained in control experiments when the Wilson protein
antibody as the primary antibody was preabsorbed with
the GST-Wilson protein-fusion protein used to raise the
antibody or when the Wilson protein antibody as the pri-
mary antibody was not added (data not shown). When
analysing skin samples from the LEC rat, which does not
express the Wilson protein, as negative control, no signal
could be obtained in the sweat glands (Figure 1C/D).
There was no obvious change of morphology of sweat
glands in LEC rat.
To investigate the role of Wilson protein in sweat gland
cells, sweat copper concentration and sweat volume was
analysed in controls and patients diagnosed with Wilson
disease.
Sweat copper concentration
Copper concentration in sweat was unaltered between the
group of Wilson patients compared to controls (Figure 2).
Statistical subgroup analysis of untreated Wilson patients
was not possible, as only 1 untreated Wilson patients
(Table 2 Nr. 45) produced enough sweat volume to deter-
mine the copper concentration. The copper concentration
determined in this single patient (3,0 μmol/l) was within
the box blot range for treated Wilson patients.
Reduced sweat volume
Wilson patients showed a significant reduction in the
sweat volume produced during the 30 min collection time
(Figure 3A). Wilson patients without therapy produced
even less sweat volume (Figure 3B).
Total copper excretion
Multiplication of the sweat volume produced during the
30 min collection time with the copper concentration
measured in the sweat sample gives the total copper excre-
tion. There was no significant difference of the total excre-
tion of copper in sweat between controls and Wilson
patients who produced more than 20 μl of sweat, so total
copper excretion could be calculated (Figure 4). There
were 5 Wilson patients producing less than 20 μl of sweat
(Table 2), so total copper excretion could not be calcu-
lated for these patients, as copper concentration could not
be determined exactly in these small volumes. 2 Wilson
51 No Wilson disease Liver 
transplantation for Budd- Chiari 
syndrom
20 F n.d. 57.0 6 months after liver 
transplantation
52 Liver cirrhosis 44 F 3.07 39.2
53 Liver cirrhosis 54 M 0.47 79.1
54 Liver cirrhosis 52 M 1.84 58.0
55 Liver cirrhosis 44 M 1.81 78.0
56 Liver cirrhosis 47 M 2.28 53.6
57 Liver cirrhosis 54 W 2.84 39.7
58 Liver cirrhosis, PSC 39 M 1.85 46.0
Table 2: Detailed data of all patients included into the study (Continued)BMC Gastroenterology 2008, 8:29 http://www.biomedcentral.com/1471-230X/8/29
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patients did not produce any sweat during the collection
time (Table 2). If Wilson patients producing no sweat
would be added to the group of Wilson patients for which
copper concentration in sweat could be determined, over-
all total copper excretion is less for Wilson Patients than
for controls. This is even more true for the subgroup of
untreated Wilson patients.
Partial reversibility
Obviously, treatment of the disease resulted in an increase
in sweat production (Figure 3B). This was not specific to
any type of treatment as no correlation between the type
of treatment (D-penicillamine/trientine/zinc) and the
amount of sweat produced by Wilson patients could be
found. During this study, one newly diagnosed patient
could be measured before and after 6 months trientine
treatment demonstrating the partial reversibility of
reduced sweat production in Wilson patients. (Table 3).
However, Wilson patients do not reach the levels of sweat
excretion of controls (Figure 3). To get further insight into
the reversibility of the reduced sweat volume in Wilson
patients one additional Wilson patient with fulminant
liver failure was analysed before liver transplantation and
several weeks thereafter. Whereas no sweat could be
obtained before transplantation there was a return of
sweat production after transplantation (Table 3). A
patient transplanted for Budd-Chiari syndrome without
signs of Wilson disease was analysed as a control after
liver transplantation.
No linear correlation could be found between the serum
copper, serum ceruloplasmin and serum non-ceruloplas-
min bound copper and the sweat copper concentration,
the sweat volume and the total copper excretion in sweat
in all test persons (data not shown). Correlations were
Sweat copper concentration Figure 2
Sweat copper concentration. Box blot graphic: Sweat 
copper concentrations are unaltered in Wilson patients com-
pared to controls. Circle: median. Bar: average. Box : 2× 
standard deviation.
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Wilson protein detection in sweat glands by immunofloures- cence Figure 1
Wilson protein detection in sweat glands by immun-
oflourescence. Frozen sections from normal rat paws 
(A+B) and LEC rat paws (C+D) and human skin (E-F) were 
incubated with the following antibodies: A-F: Anti-Wilson 
Protein Antibody followed by a red fluorescent secondary 
antibody. B+D+F: DNA couterstain with Hoechst DNA dye. 
F is the marked detail out of E. Arrows indicate the lumen of 
the sweat gland. The Wilson protein is abundantly expressed 
in the secretory and ductular epithelial cells of the sweat 
glands both in human and normal rat, but not in the LEC rat, 
which has no expression of the Wilson protein. Magnifica-
tion: A-D: 100×, E:40×, F: 600×. Bar: A-D 12 μm; E 30 μm; F 
2 μm.
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tested in pairs (e.g. serum copper- sweat copper concen-
tration in all patients and control). Multifactorial analyses
were not performed. Subgroup analyses were not per-
formed.
Discussion
Wilson protein expression
The Wilson protein is found in the epithelial cells of the
sweat gland. Even though the Wilson protein is mainly
expressed in the liver, where it has the essential role of
removing excess copper out of the body via the bile and
thereby keeping whole body copper balance, the Wilson
protein is also expressed in many other tissues, e.g. brain,
heart, lung, intestine, placenta and mammary gland
[6,20,21]. Under physiological conditions, the function
of the extrahepatic Wilson protein seems mainly supply of
copper for cellular production of cuproenzyms rather
than copper excretion out of the cell [6]. This may also be
the physiological role of the Wilson protein within the
sweat gland. The Wilson protein might also be responsi-
Table 3: Reversibility of impaired sweat excretion.
Sweat volumes before and after medical treatment
Wilson patient (No.37) initial diagnosis before therapy 0 μl
Wilson patient (No.37) after 6 months trientine therapy 31.6 μl
Sweat volumes before and after liver transplantation
Wilson patient (No. 49) before liver transplantation 0.3 μl
Wilson patient (No. 49) 6 months after liver transplantation 46.0 μl
Control patient (No. 51) 6 months after liver transplantation 57.0 μl
Sweat volume Figure 3
Sweat volume. 3A: Sweat volume of controls/Wilson patients Wilson patients produce significantly less sweat during the col-
lection period compared to controls. Wilson patients without detectable sweat volume were not included into the analysed 
groups. Circle: median. Bar: average. Box : 2× standard deviation. 3B: Sweat volumes of treated Wilson patients and untreated 
Only 4 of the 6 Wilson patients without treatment produced detectable volumes of sweat. The average sweat production of 
the 6 patients is given as a bar. Untreated Wilson patients show a very low sweat production. Bar: average. Box : 2× standard 
deviation.
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ble for copper supply to cuproenzymes critical for neuro-
transmitter processing, such as the dopamin β-
hydroxylase and tyrosinase [22], as the sweat gland is
stimulated by a complex innervation by both parasympa-
thetic and sympathetic nerve fibres with a complex inter-
action with inhibitory and agonistic signals between the
systems and the effector cell [23]. It is an emerging con-
cept for tissues with polarized cells like placenta or intesti-
num, that both, the Wilson protein and the Menkes
protein as copper-ATPases are coexpressed and regulated
e.g. by hormonal or metabolic factors [6,24]. Additional
investigations might also give insight into a potential
interplay between the Wilson protein and its "sister"-pro-
tein, the Menkes protein, in the copper metabolism of
sweat gland epithelial cells.
Sweat copper concentration
Sweat copper concentrations are unaltered comparing
Wilson patients and controls. This suggests, that the Wil-
son protein has no essential role in copper excretion into
sweat. The mechanisms of copper transport into sweat are
unknown so far. Given the increased non-ceruloplasmin
bound copper concentrations in serum and tissues as well
as the generally elevated copper concentrations in nearly
all tissues in Wilson patients, elevated copper concentra-
tions would to be expected in sweat of Wilson patients if
copper excretion into sweat would follow simple diffu-
sion, passive transport or paracellular transport from tis-
sue or serum compounds into the sweat, as described
previous for other compounds such as ethanol [17] or lac-
tate [18].
Obviously, this study is limited as it could only measure
copper concentration and the volume of the final sweat as
it gets to the surface of the skin. It is possible that concen-
trations of metals and electrolyes vary between the pri-
mary sweat fluid and the sweat secreted onto the skin due
to reabsorption and active secretion in the sweat ducts. To
analyse this in more details, studies utilizing isolated
sweat glands would be a potential way for investigations.
Reduced sweat volume
The reduced sweat volume, which is especially extreme in
untreated patients, could be explained by cellular dys-
function: Due to the reduced physiological function of the
Wilson protein or due to toxic, damaging effects caused by
the mutated protein (e.g. entrapment in the ER or forma-
tion of aggregates) as described previously for the Wilson
protein [25] and also described in other diseases with
impaired sweat productions in sweat gland cells, e.g. α-
galactosidase deficiency, Fabrys disease [26], sweat pro-
duction is impaired. Wilson protein malfunction might
also effect the function of chloride transporters which
might play a role in sweat production. Colocalization and
coimmunoprecipitation of the Wilson protein and the
Chlorid transporter ClC-4 as well as effects of the expres-
sion of ClC-4 on Wilson protein function have been dem-
onstrated before [27]. Inhibitory effects of elevated
cellular copper concentrations due to the missing cellular
excretory function of the Wilson protein could also
explain the reduction in sweat volumes in affected
patients. However, as cellular copper concentrations
could not be analysed in this study, this remains specula-
tive. Potential influences of additional factors e.g. hypo-
proteinemia, age, race and skin conditions have not been
analysed in this pilot study but might be relevant [28].
On the other hand, the data shows a clear increase of
sweat volume when the Wilson disease patients are
treated either by medication (D-penicillamine/trientine/
zinc) or after liver transplantation (Figure 3B, Table 3).
Under either treatment, the malfunction or absence of the
Wilson protein within the epithelial sweat gland cell
remains unchanged. However, liver transplantation
results in an excretion of excessive and accumulated cop-
per via the biliary fluid normalizing whole body copper
concentrations over time. Medical treatment with the
chelating agents D-penicillamine and trientine or treat-
ment with zinc, which blocks copper absorption and
induces copper-binding metallothionin within the body,
all result in a netto efflux of copper out of the body and
lowering of non-ceruloplasmin bound copper concentra-
tions all over the body. This reduction of toxic copper and
overall and cellular copper load allows damaged cells to
Total copper excretion Figure 4
Total copper excretion. The total amount of copper 
excreted into sweat did not differ significantly between the 
controls and all Wilson patients producing more than 20 μl 
sweat. Circle: median. Bar: average. Box : 2× standard devia-
tion.
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regenerate and function normally. The same may be true
for the sweat gland cells. Especially hepatocytes and neu-
ronal cells, which are mainly affected during the course of
Wilson disease benefit from Wilson medications or trans-
plantation. One might even speculate, that impairment
and partial regeneration of the autonomous nervous sys-
tem innervating the sweat gland cells by the complex sym-
pathetic postganglionar cholinergic innervation of the
sweat gland, explains the reduced and partially reversible
sweat production in Wilson patients. Malfunction of the
autonomous nerve system and their partial or complete
normalization have been described in Wilson patients for
regulation of cardiovascular functions, saliva production
and sympathetic skin response [3,29,30] before.
Even though the sweat test is a non-invasive test, it does
not add any clinical value to the diagnosis of Wilson dis-
ease as the established serum markers ceruloplasmin and
copper were more accurate in differentiating controls
from Wilson patients.
Conclusion
The Wilson protein is expressed in the sweat gland epithe-
lial cells. In Wilson disease, there is an impairment of
sweat production. Impairment of sweat production can be
improved by standard medical therapy for Wilson disease
or by liver transplantation. Wilson patients do not com-
pensate for reduced biliary copper excretion by an
increased sweat copper excretion. The impairment of
sweat production might be of relevance for thermoregula-
tion for Wilson patients.
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